(Press-News.org) Highlights:
Resistance to colistin, a potent antibiotic, is on the rise.
In 2016, researchers discovered that colistin resistance could be transferred laterally among microbes.
Researchers have isolated genes that confer colistin resistance from imported seafood purchased from markets in Atlanta, Ga.
The findings suggest imported seafood could promote the spread of transmissible colistin resistance.
Los Angeles, Calif.—Colistin is a potent, last-resort antibiotic, used only to treat people with dangerous, life-threatening bacterial infections that have developed resistance to other drugs. But it’s not foolproof. Worldwide, resistance to colistin is spreading, further diminishing treatment options and putting infected people at higher risk.
Researchers from the University of Georgia recently identified a way that colistin resistance genes are spreading: Imported seafood. In a new study, microbiologist Issmat Kassem, Ph.D., and his group have reported the first isolation of colistin-resistance genes in bacteria found in imported shrimp and scallops, purchased from 8 food markets around Atlanta, Ga. Kassem will be presenting the findings this week in Los Angeles at ASM Microbe 2025, the annual meeting of the American Society for Microbiology. An accompanying paper will be published in the ASM journal mSphere.
“We love our seafood,” Kassem said. Many people don’t know that most seafood consumed in the U.S. is imported, he said, including about 90% of shrimp. Imported seafood is screened for contaminants but the process doesn’t catch everything, especially antimicrobial resistance genes. “The bacteria that were carrying colistin resistance genes are not normally screened.” Kassem and his group also found that some of the resistance genes are carried on plasmids—round bits of genetic material that can be transmitted from bacteria to bacteria.
Antimicrobial resistant infections kill hundreds of thousands of people globally every year, and antimicrobial resistance is a rising public health menace. Colistin was first introduced in the 1950s to treat infections by pathogenic Gram-negative bacteria, but it takes a heavy toll on patients, including increased risk of damage to the nerves and kidneys. It was discontinued in the U.S. in the 1980s. However, Kassem noted, other countries continued to use it in agricultural settings, both to treat infections and to promote animal growth. Colistin was eventually reintroduced to human medicine because it was one of the few options available to treat certain bacterial infections. The World Health Organization categorizes colistin as a high priority critically important antibiotic, which means it is an essential option for treating serious human infections.
In 2016, researchers discovered a mobile colistin resistant gene, or mcr, that was “mobile” because it could be transferred via lateral transmission, in plasmids passed among bacteria. Before then, Kassem said, researchers believed colistin resistance was inherited, not shared, “which means it could not jump between different bacteria.”
Researchers have now identified at least 10 mcr genes and many alleles, or variations. Kassem, who has been studying antimicrobial resistance for 2 decades, suspected it might spread through the importing and exporting of food.
“Our food is sourced from different places,” he said. “If you go out to lunch today, your plate might have ingredients from 6, 7, 8 countries. Some countries do not have strict regulations for using antibiotics in food animal production, so imported food can be a vehicle for transmission of resistance.” In previous work, his group found mcr genes in samples from wastewater in Georgia; they also found the bacterial host that was carrying the plasmid containing the genes. It wasn’t normally screened in food coming into the United States, he said. In studies published since then, researchers have found mcr genes in plasmids elsewhere.
When they screened seafood purchased from markets in Georgia, they found the same bacterial host, the same plasmids and the same genes that they’d previously identified in wastewater. “The good news is that we didn’t find it in locally produced seafood,” Kassem said.
He cautioned that the group identified 1 source of colistin resistance, but there could be other, and they’re likely spreading. “We live in a very connected world,” he said. “We move a lot, we travel a lot, our food travels, and we are going to spread whatever emerges, even across national borders. So, it’s important to invest in monitoring systems and expand them and collaborate, especially on the global level, on the issue of antimicrobial resistance.”
###
The American Society for Microbiology is one of the largest professional societies dedicated to the life sciences and is composed of over 37,000 scientists and health practitioners. ASM's mission is to promote and advance the microbial sciences.
ASM advances the microbial sciences through conferences, publications, certifications, educational opportunities and advocacy efforts. It enhances laboratory capacity around the globe through training and resources. It provides a network for scientists in academia, industry and clinical settings. Additionally, ASM promotes a deeper understanding of the microbial sciences to all audiences.
END
Antimicrobial resistance genes hitch rides on imported seafood
2025-06-22
ELSE PRESS RELEASES FROM THIS DATE:
New way to find “aged” cells marks fresh approach for research into ageing
2025-06-21
Tokyo, Japan – Researchers from Tokyo Metropolitan University have created a new way of telling “aged” human cells apart from younger ones using electric fields. While key markers have been found for these “senescent” cells, current methods require biochemical “labels” which are difficult to apply and affect the cells themselves, making them difficult to study. The new method is label-free and less damaging. The team aims to diversify the method, extending it to other cell types.
Ageing starts at the cellular level. As we get older, aged or “senescent” cells accumulate in our body. Not only have ...
From blood sugar to brain relief: GLP-1 therapy slashes migraine frequency
2025-06-20
(Helsinki, Finland, Saturday, 21 June 2025) A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new study presented today at the European Academy of Neurology (EAN) Congress 2025.1
Researchers at the Headache Centre of the University of Naples “Federico II” gave the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide to 26 adults with obesity and chronic migraine (defined as ≥15 headache days per month). Patients reported an average of 11 fewer headache days per month, while disability scores on the Migraine Disability Assessment Test ...
Variability in heart rate during sleep may reveal early signs of stroke, depression or cognitive dysfunction, new study shows
2025-06-20
(Helsinki, Finland, Saturday, 21 June 2025) New research, presented today at the European Academy of Neurology (EAN) Congress 2025, has uncovered a powerful link between nighttime heart rhythm and future health conditions, even in people with no obvious sleep problems.1
The study, which was conducted at the Department of Neurology, Inselspital, the University Hospital of Bern, analysed 4,170 individuals over an observation period of 13,217 person-years, found that heart rate variability (HRV) during sleep can serve ...
New method to study catalysts could lead to better batteries
2025-06-20
Scientists and engineers study the atomic interactions that happen on the surface of materials to develop more energy efficient batteries, capacitors, and other devices. But accurately simulating these fundamental interactions requires immense computing power to fully capture the geometrical and chemical intricacies involved, and current methods are just scratching the surface.
“Currently it’s prohibitive and there’s no supercomputer in the world that can do an analysis like that,” says Siddharth Deshpande, an assistant professor in the University of Rochester’s Department of Chemical Engineering. “We need clever ways to manage ...
Current Molecular Pharmacology impact factor rises to 2.9, achieving Q2 ranking in the Pharmacology & Pharmacy category in 2024 JCR
2025-06-20
June 18, 2025 - The highly anticipated 2024 Journal Citation Reports (JCR) were officially released today, marking a significant achievement for Current Molecular Pharmacology (CMP). The journal's 2024 Impact Factor has increased to 2.9, with a five-year Impact Factor of 3.1, successfully advancing to the Q2 zone in the PHARMACOLOGY & PHARMACY category. This accomplishment signifies a notable enhancement in CMP's academic influence and recognition.
CMP is dedicated to publishing the latest advancements ...
More time with loved ones for cancer patients spared radiation treatment
2025-06-20
For many patients, radioactive iodine treatment after thyroid cancer surgery means side effects like nausea and time in hospital isolated from loved ones. But new clinical trial results from researchers at UCL mean hundreds of thousands of patients worldwide could now safely be spared this treatment.
Globally, around 820,000 people are diagnosed with thyroid cancer each year. Compared to most cancers, it affects a high proportion of younger people who are more likely to be parents to young children. It is also three times more common in women than men.
The Iodine or Not (IoN) clinical ...
New methods speed diagnosis of rare genetic disease
2025-06-20
NEW YORK, NY (June 20, 2025)—A new laboratory method developed by researchers at Columbia University Vagelos College of Physicians and Surgeons may now help physicians more quickly diagnose patients with suspected genetic disorders of the immune system, many who have been trapped in diagnostic limbo for years.
The researchers, who published their findings June 20 in Cell, applied the method to one rare inborn error of immunity called activated-PI3Kδ syndrome (APDS) and found dozens of additional genetic variations that could cause the syndrome.
“Our findings give physicians a resource that can help them rapidly diagnose and treat ...
Genetics of cardiomyopathy risk in cancer survivors differ by age of onset
2025-06-20
(MEMPHIS, Tenn. – June 20, 2025) The relationship between genetic variants and the risk of late-onset cardiomyopathy remains poorly understood in survivors of childhood cancer despite being otherwise well established. Scientists from St. Jude Children’s Research Hospital have helped address this gap, assessing whether variant trends seen in the general population also apply to late-onset cardiomyopathy in five-year survivors of childhood cancer. The work revealed that, as in the general population, common variants in TTNand BAG3 are associated with reduced late-onset cardiomyopathy ...
Autism inpatient collection releases genetic, phenotypic data for more than 1,500 children with autism
2025-06-20
The Simons Foundation Autism Research Initiative (SFARI) has released phenotypic and genetic data from the Autism Inpatient Collection (AIC), a cohort of more than 1,500 youth participants ages 4 to 20 years old who were hospitalized in one of six child psychiatry units in the United States. The AIC, supported by SFARI and the Nancy Lurie Marks Family Foundation, aimed to engage these individuals, many of whom meet recently proposed criteria for ‘profound autism’ (autism characterized by intellectual disability or minimal language that requires high ...
Targeting fusion protein’s role in childhood leukemia produces striking results
2025-06-20
Scientists at St. Jude Children’s Research Hospital and Dana-Farber Cancer Institute today report the identification of a novel combination therapy approach to treat pediatric acute myeloid leukemia (AML). Standard treatment is often ineffective against AML, a cancer that commonly relapses with poor prognosis, particularly when the disease is fueled by fusion proteins involving NUP98. The researchers documented how these fusions drive disease, discovering a protein complex required to express cancer-promoting genes. When they targeted the complex alone or in combination with another anticancer drug, survival significantly ...